

http://www.aimspress.com/journal/MBE

MBE, 18(6): 9474–9495. DOI: 10.3934/mbe.2021465 Received: 24 September 2021 Accepted: 25 October 2021 Published: 29 October 2021

Research article

Threshold dynamics and optimal control on an age-structured SIRS epidemic model with vaccination

Han Ma and Qimin Zhang*

School of Mathematics and Statistics, Ningxia University, Yinchuan, 750021, China

* Correspondence: Email: zhangqimin64@sina.com.

Abstract: We consider a vaccination control into a age-structured susceptible-infective-recoveredsusceptible (SIRS) model and study the global stability of the endemic equilibrium by the iterative method. The basic reproduction number R_0 is obtained. It is shown that if $R_0 < 1$, then the disease-free equilibrium is globally asymptotically stable, if $R_0 > 1$, then the disease-free and endemic equilibrium coexist simultaneously, and the global asymptotic stability of endemic equilibrium is also shown. Additionally, the Hamilton-Jacobi-Bellman (HJB) equation is given by employing the Bellman's principle of optimality. Through proving the existence of viscosity solution for HJB equation, we obtain the optimal vaccination control strategy. Finally, numerical simulations are performed to illustrate the corresponding analytical results.

Keywords: SIRS epidemic model; age-structure; threshold dynamics; optional control; Hamilton-Jacobi-Bellman (HJB) equation

1. Introduction

The susceptible-infective-removed-susceptible (SIRS) model is one of the most popular epidemic models, in which total host population is divide into three classes called *susceptible* (*S*), *infective* (*I*) and *removed* (*R*). Since the Kermack and McKendrick pioneering work [1], a large number of studies have been carried out on the model of continuous infectious diseases attempting to gain a better understanding of diseases transmission, especially for the control policies and dynamics [2–5]. Recent years, many researchers have studied the epidemic with SIRS models such as COVID-19(2019), hand-foot-and-mouth diseases(HFMD) and other infectious diseases recently. Although scholars have flocked to study many properties of the SIRS models, there are still many aspects that deserve further study, such as the threshold dynamics of SIRS model with vaccination and optimal control using dynamic programming method.

In studying the dynamics of the disease, one of the most important concepts is the basic reproduc-

tion number R_0 . It is epidemiologically defined as the expected number of secondary cases produced by a typical infectious individual during its entire infectious period in a completely susceptible host population. To investigate the global behavior of the prevalence of infectious diseases, the stability analysis of equilibrium for epidemic models have been carried out (see [6, 7] and the references therein). For ordinary differential SIRS models, Mena-Lorca and Hethcote considered several kinds of SIRS epidemic models and a threshold parameters were also found in [6] to determine whether the disease dies out or approaches to an endemic equilibrium, we also note that the global stability of SIRS epidemic model have already been investigated and the threshold theorems are well obtained. In the subsequent studies, it was generally believed that the introduction of age-structure into epidemic models is necessary and reasonable. Since the fact that the age structure of a population affects the dynamics of disease transmission was recognized, various age-structured epidemic models have been investigated by many authors. Some theoretics on the transmission dynamics of age-structured epidemic models have been developed in [8–11]. He et al. [12] studied the optimal birth control of age-dependent competitive species. Yang et al. [13] proposed epidemic model with age-since-infection and diffusion, the next generation operator R is also given as the basic regeneration numbers. In paper [14], Yang et al. also studied the threshold dynamics by the method of Lyapunov functionals for an age-of-infection epidemiological model with nonlinear incidence rate. Chekroun et al. [15] showed the stability of the equilibrium by using Lyapunov functions. Lan et al. [16] just studied the impact of hospital resources and environmental perturbation to the dynamics of SIRS model. But the effect of vaccination on threshold dynamics was not considered in these articles.

In fact, we notice that vaccination has a significant impact on the thresholds dynamics of many infectious diseases, such as COVID-19, HPV, etc. Obviously, vaccination of susceptible individuals can greatly reduce the probability that susceptible individuals become infected. Thus, decision makers hope to achieve the optimal proportion of vaccines with the lowest cost. Optimal control is a promising strategy to control disease outbreaks. The main purpose of using the control in some diseases is to search for the most effective one that reduces the infection to a minimum level while minimizing the cost of applying control measures. In papers [7,9,17], the strategies such as health promotion campaigns or lockdown policies can contribute to reducing the disease transmission. In paper [18], Mu and Zhang investigated the near-optimal control of SIRS multi-strain epidemic model with age-structure using Pontryagin maximum principle. Bolzoni et al. [19] investigated optimal control of epidemic size and duration with limited resources. In papers [21–23], some measures correspond to screening and quarantining of infected were implemented to achieve the purpose of controlling the disease.

However, we note that the most of these articles by using maximum principle to show optimal controls and only present necessary conditions. Defectively, the method of maximum principle only addresses the optimal control problem with initial value case of $t_0 = 0$. In fact, vaccination can be administered at any time $t = t_0$ in the control of the disease. Surpassingly, the dynamic programming method can give the necessary and sufficient conditions for the existence of optimal control via the HJB equation at any initial times $t = t_0$ and initial states. In other words, the dynamic programming method is an extension of the maximum principle, namely, the dynamic programming method is equivalent to maximum principle method when $t_0 = 0$.

Overall, the threshold dynamics results about age-structured SIRS epidemic models with the pro-

portion of the vaccine injections are comparatively scarce, as well as few articles show that dynamic programming approach to solve the optimal control problem. Thus, in this paper, taking into account for the effect of the proportion of the vaccine injections, we incorporate the vaccine injection rate in solving the threshold of age-structured SIRS epidemic models. And vaccination optimal control is also obtained through dynamic programming approach.

The layout of this paper is as follows: in section 2, an age-structure SIRS epidemic model is reproduced and new age-structure SIRS epidemic model with vaccination is given; in section 3, we give the basic regeneration number and discuss the threshold dynamics; in section 4, we formulate and solve the corresponding optimal control problem. The existence of optimal control is proved by HJB equation and the expression of optimal control is present. in section 5, some numerical simulations are performed to demonstrate the theoretical results. Brief conclusions are given in section 6.

2. Model and preliminaries

We reproduce the age-structured SIRS epidemic model based on paper [24] as follows

$$\begin{cases} dS(a,t) = \left[-\frac{\partial S(a,t)}{\partial a} + \lambda(a) - \mu(a)S(a,t) - \beta(a)S(a,t)I(a,t) + \rho(a)\eta(a)I(a,t) \right] dt, \\ dI(a,t) = \left[-\frac{\partial I(a,t)}{\partial a} + \beta(a)S(a,t)I(a,t) - \delta(a)I(a,t) \right] dt, \\ dR(a,t) = \left[-\frac{\partial R(a,t)}{\partial a} + (1 - \rho(a))\eta(a)I(a,t) - (\mu(a) + \gamma(a))R(a,t) \right] dt, \\ S(a,0) = S_0(a), I(a,0) = I_0(a), R(a,0) = R_0(a), \end{cases}$$
(2.1)

where $S(a, 0) = S_0(a)$, $I(a, 0) = I_0(a)$, $R(a, 0) = R_0(a)$ are initial conditions, with the following conditions:

$$\begin{cases} S(0,t) = \int_{0}^{A} \beta(a) S(a,t) da, \\ I(0,t) = k_{1} \int_{0}^{A} \beta(a) I(a,t) da, \\ R(0,t) = k_{2} \int_{0}^{A} \beta(a) R(a,t) da, \end{cases}$$
(2.2)

where $k_1, k_2 \in [0, 1]$ present the weight of the infected and recovered, respectively. All the parameters are related to age *a*, positive and bounded, These parameters and their meaning are listed in the Table 1, where $\eta(a) = \sigma(a) + \alpha(a)$, and $\delta(a) = \mu(a) + \phi(a) + \sigma(a) + \alpha(a)$.

As we all know that the age density distribution function of the total population reaches a stable state, i.e

$$S(a,t) + I(a,t) + R(a,t) = P(a).$$
 (2.3)

We focus on threshold dynamics on an age-structured SIRS epidemic model with vaccination. The spread of many epidemics are age-related, such as Human Papilloma Virus (HPV) spread across the population after ten years olds usually. And the World Health Organization believes that the most appropriate age for HPV vaccination was 11-12 years old. Therefore, it makes sense to study the vaccination is only given for a certain age to age-structured SIRS epidemic model.

The introduced vaccination rate $u(A_0)$ satisfies $0 \le u(A_0) \le 1$ and is only given for a certain age and susceptible individuals of age A_0 is inoculated at some point. The disease does not spread among people younger than age A_0 , that is, there are no patients before the vaccination age A_0 . Therefore, we can get that the system satisfied by the susceptible, infective, and recovering individuals based on

Notation	Biological meanings	
S(a,t)	Densities of susceptible individuals of age <i>a</i> at time <i>t</i>	
I(a,t)	Densities of infective individuals of age <i>a</i> at time <i>t</i>	
R(a,t)	Densities of recovery individuals of age <i>a</i> at time <i>t</i>	
$\lambda(a)$	Recruitment rate of age a	
$\mu(a)$	Mortality rate of age <i>a</i>	
$\beta(a)$	Transmission coefficient of age a	
$\gamma(a)$	Immunity loss rate of age <i>a</i>	
$\delta(a)$	Infected removal rate of age <i>a</i>	
$\eta(a)$	Infected recovery rate of age <i>a</i>	
$\rho(a)$	Switch between $SIS \leftrightarrow SIR(S)$ of age a	
$\alpha(a)$	Treatment rate of age <i>a</i>	
$\sigma(a)$	Nature cure rate of age <i>a</i>	
$\phi(a)$	Infected-induced mortality rate of age a	

Table 1. Parameter values used in numerical simulations.

model (2.1) as following

$$\begin{split} S(a,t) &= P(a), \ I(a,t) = 0, \ R(a,t) = 0, \ 0 < a < A_0, \\ dS &= (-\frac{\partial S}{\partial a} + \lambda(a,t) - \mu(a)S - \varrho(a,t)S + \rho(a)\eta(a)I)dt, \ A_0 < a < A, \\ dI &= (-\frac{\partial I}{\partial a} + \varrho(a,t)S - \delta(a)I)dt, \ A_0 < a < A, \\ dR &= (-\frac{\partial R}{\partial a} + (1 - \rho(a))\eta(a)I - \mu(a)Rdt, \ A_0 < a < A, \\ S(A_0,t) &= (1 - u(A_0))S(A_0^-,t), \\ I(A_0,t) &= I(A_0^-,t) = 0, \\ R(A_0,t) &= u(A_0)S(A_0^-,t), \\ S(a,0) &= S_0(a), \ I(a,0) = I_0(a), \ R(a.0) = R_0(a), \\ \varrho(a,t) &= k(a) \int_{A_0}^A I(\hat{a},t)d\hat{a}, \end{split}$$
(2.4)

we call infectivity

$$\varrho(a,t) = \beta(a)I(a,t) = k(a)\int_{A_0}^A I(\hat{a},t)d\hat{a} < \infty,$$

where $S(A_0^-, t)$ and $I(A_0^-, t)$ are the densities of susceptible and recovering individuals in the left neighborhood of age A_0 , k(a) is a positive continuous function. The vaccination rate $u(A_0)$ is a constant and k(a) is a nonnegative continuous function defined on $0 \le a \le A$, where A is the maximum age.

In this paper, unless otherwise specified. The H represents the Hilbert space, with inner product

$$\langle \varphi_1, \phi_1 \rangle = \int_0^A \varphi_1(a) \phi_1(a) da, \ \varphi_1, \ \phi_1 \in \mathbb{H},$$
(2.5)

and we consider the state equations on space $L^1(0, A; \mathbb{H}^3)$, when $\varphi = (\varphi_1, \varphi_2, \varphi_3)$ and $\phi = (\phi_1, \phi_2, \phi_3)$, $\varphi_i, \phi_i \in \mathbb{H}$, the definition of inner product on $L^1(0, A; \mathbb{H}^3)$ as

$$\langle \varphi, \phi \rangle = \int_0^A (\varphi_1(a)\phi_1(a) + \varphi_2(a)\phi_2(a) + \varphi_3(a)\phi_3(a))da = \int_0^A \varphi^\top(a)\phi(a)da, \ \varphi, \ \phi \in \mathbb{H}^3.$$
(2.6)

Mathematical Biosciences and Engineering

3. Threshold dynamics

The existence of time-independent equilibrium solutions for the model (2.4) is discussed. Obviously, the model (2.4) has disease-free equilibrium

$$S(a,t) = P(a), \quad I(a,t) = 0, \quad R(a,t) = 0, \quad 0 < a < A_0,$$

$$S(a,t) = (1 - u(A_0))P(a), \quad I(a,t) = 0, \quad R(a,t) = u(A_0)P(a), \quad A_0 < a < A.$$
(3.1)

In order to obtain the endemic disease equilibrium solution, S(a, t) = S(a), I(a, t) = I(a) and R(a, t) = R(a) are substituted into the model (2.4) obtained

$$R(a) = 0, \qquad 0 < a < A_0, R(a) = u(A_0)P(a), \qquad A_0 < a < A.$$
(3.2)

And we know when $R_0(a) = u(A_0)P(a)$, the $R(a, t) = u(A_0)P(a)$, and when the population reaches a dynamic equilibrium P(a), Combining the equations (2.3) and (3.2), and substitute into (2.4) for the equation that satisfies I(a, t). From (2.3), it shows that

$$\frac{\partial I(a)}{\partial a} + \frac{\partial I(a)}{\partial t} = -\delta(a)I(a) + k(a)(P(a) - I(a) - R(a))D(t), \tag{3.3}$$

where $D(t) = \int_{A_0}^{A} I(\hat{a}, t) d\hat{a}$. Let $\zeta(a, D(t)) = \delta(a) + k(a)D(t)$, in order to solve the (3.3), when $A_0 < a < A$, the expression of I(a, t) is

$$I(a,t) = I_0(a-t)exp(-\int_0^t \zeta(a-t+\theta, D(\theta))d\theta)$$

+ $[1-u(A_0)] \int_0^t exp(-\int_\tau^t \zeta(a-t+\theta, D(\theta))d\theta)$
× $k(a-t+\theta)P(a-t+\theta)D(\tau)d\tau, \quad a > t+A_0,$
$$I(a,t) = [1-u(A_0)] \int_{A_0}^a exp(-\int_\tau^a \zeta(\theta, D(t-a+\theta))d\theta)$$

× $k(\tau)P(\tau)D(t-a+\tau)d\tau, \quad a \le t+A_0.$ (3.4)

we can substitute (3.4) into the D(t) yields when $A_0 < a < A$

$$D(t) = [1 - u(A_0)] \int_{A_0}^{A} \int_{A_0}^{a} k(\tau) P(\tau) D(t - \tau)$$

$$\times exp(-\int_{a}^{a+\tau} \zeta(\theta, D(t - a - \tau + \theta)) d\theta) dad\tau$$

$$+ \int_{A_0}^{a} I_0(a) exp(-\int_{0}^{t} \zeta(a + \theta, D(\theta)) d\theta) da.$$
(3.5)

Since

$$\lim_{t\to\infty}\int_{A_0}^a I_0(a)exp(-\int_0^t \zeta(a+\theta,D(\theta))d\theta)da \leq \int_{A_0}^a I_0(a)exp(-\int_0^t \mu(a+\theta,N)d\theta)da = 0,$$

Mathematical Biosciences and Engineering

obviously, we have $D(t) = D_{\infty}$ if $I(a, t) = I_{\infty}$ as $t \to \infty$ is equilibrium of model, then

$$D_{\infty} = [1 - u(A_0)] \int_{A_0}^{A} \int_{A_0}^{a} k(\tau) P(\tau) \cdot exp(-\int_{a}^{a+\tau} \zeta(\theta, D_{\infty}) d\theta) D_{\infty} da d\tau + \int_{A_0}^{a} I_0(a) exp(-\int_{0}^{t} \zeta(a+\theta, D_{\infty}) d\theta) da,$$
(3.6)

then

$$D_{\infty} = D_{\infty} [1 - u(A_0)] \int_{A_0}^{A} \int_{A_0}^{a} k(\tau) P(\tau) \cdot exp(-\int_{a}^{a+\tau} \delta(\theta) d\theta) \\ \times exp(-D_{\infty} \int_{a}^{a+\tau} k(\theta) d\theta) d\tau da.$$
(3.7)

Then it expresses $I_{\infty} = 0$ or

$$1 = [1 - u(A_0)] \int_{A_0}^{A} \int_{A_0}^{a} k(\tau) P(\tau) \cdot exp(-\int_{a}^{a+\tau} \delta(\theta) d\theta) \\ \times exp(-D_{\infty} \int_{a}^{a+\tau} k(\theta) d\theta) d\tau da.$$
(3.8)

It is quite obvious the right-hand side of the equation (3.8) is the minus function about D_{∞} , thus, we can define

$$R_0 = (1 - u(A_0)) \int_0^A \int_{A_0}^a k(\tau) p_\infty(\tau) \cdot exp\left(-\int_\tau^a \delta(\theta) d\theta\right) d\tau da.$$
(3.9)

When $R_0 < 1$, (3.7) has only a unique zero solution and no positive root, when $R_0 > 1$, the (3.7) formula has zero root and the only positive root $I^* > 0$ satisfies (3.8) formula, thus there are only positive root $E^* = (S^*, I^*, R^*)$ of (2.4). For ease of analysis, we converse $i(a, t) = \frac{I(a,t)}{(1-u(A_0))P}$, equation (2.4) about I(a, t) can be transformed into

$$\begin{cases} \frac{\partial i(a,t)}{\partial t} + \frac{\partial i(a,t)}{\partial a} = [1 - i(a,t)][1 - u(A_0)]k(a) \int_{A_0}^A P(\hat{a})i(\hat{a},t)d\hat{a} - \delta(a)i(a,t), \quad a > A_0, \\ i(A_0,t) = 0, \quad t \ge 0, \\ i(a,0) = i_0(a) = \frac{I_0(a)}{(1 - u(A_0))P}, \quad a \le A_0. \end{cases}$$
(3.10)

From the transformation, we can see that the existence and stability of the positive equilibrium of model (2.4) is equivalent to positive equilibrium of (3.10) model. R_0 can be used as a threshold for the existence or absence of endemic diseases. It is also a threshold for the disappearance of diseases. Let $\hbar = 1 - \frac{1}{R_0}$ and we call \hbar vaccination elimination point.

Similar to the [25] method, the following conclusion can be obtained. Before discussing the global stability of equilibriums, we first propose the lemma 3.1, and the similar proof process have been presented in [26].

Lemma 3.1. Let $i_1(a, t)$ and $i_2(a, t)$ are the solutions of the (3.10) equations, satisfying $i_1(a, 0) = i_{10}(a) \le i_2(a, 0) = i_{20}(a)$, where $i_{10}(a)$, $i_{20}(a) \in K$, then there are following properties

Mathematical Biosciences and Engineering

- (1) $i_i(a,t) \in K, j = 1, 2;$
- (2) $i_1(a,t) \le i_2(a,t), t \ge 0;$
- (3) When $0 < \xi < 1$, the solution i(a, t) of (3.10) that the initial value satisfies the $i(a, 0) = i_{10}(a)\xi$, then it must satisfy the $i_1(a, t)\xi \le i(a, t)$,

where the K is denoted

$$K = \{ f(a,t) | f(a,t) \in C, f(0,t) = 0, 0 \le f(a,t) \le 1 \}.$$

Theorem 3.2. When $R_0 < 1$, the model (3.10) has only a disease-free equilibrium, which is globally asymptotically stable, while when $R_0 > 1$, the model (3.10) also has a unique endemic equilibrium E^* , which is globally asymptotically stable and the disease-free equilibrium is unstable.

Proof. We only consider the asymptotic behavior of solutions where the initial values of the model (3.10) satisfy $0 \le i(a, 0) \le 1$ in (A_0, A) . The theorem of the global stability is given for solutions.

It is not difficult to see if the model (3.10) has a positive equilibrium equivalent to the (3.5) has a positive root. Since the right of the (3.5) is reduced about D(t) and tends to zero when the D(t) tends to positive infinity. There is no positive real root to the (3.5) when $R_0 < 1$, and there is a unique positive real root when $R_0 > 1$, i.e. the model (2.4) has only a unique positive equilibrium when $R_0 > 1$ and, instead, no positive equilibrium when $R_0 < 1$.

When $R_0 < 1$, in order to study the global stability of the disease-free equilibrium, expression of the solution of (3.10) about I(a, t) is obtained by using the characteristic line method

$$i(a,t) = i_0(a-t)exp\left(-\int_0^t [\delta(a-t+\tau) + [1-u(A_0)]k(a-t+\tau)\int_{A_0}^A P(\hat{a})i(\hat{a},\tau)d\hat{a}]d\tau\right) + \int_0^t [1-u(A_0)]k(a-t+\tau)\int_{A_0}^A P(\hat{a})i(\hat{a},\tau)d\hat{a} \\ \times exp\left(-\int_{\tau}^t [\delta(a-t+\theta) + [1-u(A_0)]k(a-t+\theta)\int_{A_0}^A P(\hat{a})i(\hat{a},\theta)d\hat{a}]d\theta\right)d\tau, \ a \ge t+A_0,$$
(3.11)

$$i(a,t) = \int_{A_0}^{a} [1 - u(A_0)]k(\tau) \int_{A_0}^{A} P(\hat{a})i(\hat{a},t-a+\tau)d\hat{a} \times exp\Big(-\int_{\tau}^{a} [\delta(\theta) + [1 - u(A_0)]k(\theta) \int_{A_0}^{A} P(\hat{a})i(\hat{a},t-a+\theta)]d\theta\Big)d\tau, \ a < t + A_0.$$
(3.12)

When t > A, we obtain

$$i(a,t) = \int_{A_0}^{a} [1 - u(A_0)]k(\tau)\chi(t - a + \tau) \times exp\Big(-\int_{\tau}^{a} [\delta(\theta) + [1 - u(A_0)]k(\theta)\chi(t - a + \theta)]d\theta \Big) d\tau, \ a < t + A_0,$$
(3.13)

where $\chi(t) = \int_{A_0}^{A} P(\hat{a})i(\hat{a}, t)d\hat{a}$, when t < A, the $\chi(t)$ satisfy is

$$\chi(t) = [1 - u(A_0)] \int_0^A P(\hat{a}) \int_{A_0}^a k(\tau) \chi(t - \hat{a} + \tau)$$

$$\times exp\left(-\int_{\tau}^{\hat{a}} [\delta(\theta) + [1 - u(A_0)]k(\theta)\chi(t - \hat{a} + \theta)]d\theta\right) d\tau d\hat{a}, \ a < t + A_0.$$
(3.14)

Mathematical Biosciences and Engineering

For natural numbers n > 1, let $\chi_n = \max_{nA \le t \le (n+1)A} \chi(t)$, $L_n = \max\{\chi_{n-1}, \chi_n\}$. According to the (3.14) when $R_0 < 1$, we get

$$\chi(t) \leq [1 - u(A_0)] \int_0^A P(\hat{a}) \int_{A_0}^{\hat{a}} \chi(t - \hat{a} + \tau) \cdot exp\left(-\int_{\tau}^{\hat{a}} \delta(\theta) d\theta\right) d\tau d\hat{a}$$

$$\leq R_0 \max_{t - A \leq \tau \leq t} \chi(\tau).$$
(3.15)

So we obtain $\chi(t) \le R_0 \max{\{\chi_{n-1}, \chi_n\}}$ when $nA \le t \le (n+1)A$. Because of $R_0 < 1$, we also obtain $\chi_n < L_n = \chi_{n-1}$, i.e. $\chi_n < \chi_{n-1}, \chi_n$ is monotonous and reduced and $\chi_n < \chi_{n-1}R_0$, from this delivery $\lim_{n \to +\infty} \chi_n = 0$. Considering above conditions and (3.13) can also derive $\lim_{t \to +\infty} i(a, t) = 0$. Finally, it is concluded from (3.13) that the disease-free equilibrium of the model (3.10) is stable $R_0 < 1$.

When $R_0 > 1$, substituting i(a, t) = i(a) into the (3.10), the only endemic equilibrium of (3.10) is given by

$$i(a) = [1 - u(A_0)] \int_{A_0}^{a} k(a) \int_{A_0}^{A} P(\hat{a})i(\hat{a})d\hat{a} \times exp\Big(-\int_{\tau}^{a} \delta(\theta) + [1 - u(A_0)]k(\tau) \int_{A_0}^{A} P(\hat{a})i(\hat{a})d\hat{a}d\theta\Big)d\tau.$$
(3.16)

When $A_0 \le a < A$, the $\forall i(a, t)$ satisfy i(a, 0) > 0, and $\chi(t) > 0$ can be derived from (3.12) and (3.14) when $0 \le t \le A$, and we also know that i(a, A) > 0 ($A_0 < a < A$) by (3.13). Repeat this process then the $\chi(t) > 0$ is obtained when $0 \le t \le 3A$, let $\chi^0 = \min_{A \le t \le 2A} \chi(t), \chi^* = \max_{A \le t \le 2A} \chi(t)$, the following is got as

$$i(a, 2A) \ge [1 - u(A_0)] \int_{A_0}^a \chi^0 k(\tau)$$

$$\times exp\left(-\int_{\tau}^a (\delta(\theta) + [1 - u(A_0)]\chi^* k(\theta))d\theta\right) d\tau.$$
(3.17)

Comparing the forms of (3.16) and (3.17), we can find a positive number $0 < \xi < 1$ such that $i(a, 2A) \ge \xi i(a)$, namely, the following formula holds for the solution i(a, t) of (2.4)

$$\xi \cdot i(a) \le i(a, 2A) \le 1.$$

The Lemma 3.1 shows that the solutions $i_{\xi}(a, t)$ and $i_1(a, t)$ with initial values of $\xi \cdot i(a, 0)$ and 1 respectively when t = 0, must have

$$i_{\xi}(a,t) \le i(a,t+2A) \le i_1(a,t).$$

Based on the fact that i(a) is the equilibrium of (3.10), then the $\xi i(a) \le i_{\xi}(a, t)$, i.e. $i_{\xi}(a, t)$ is a monotone increasing function about t. Since $i_1(a, t)$ is a monotone subtraction function about t, and the corresponding $\chi_{\xi}(t)$ and $\chi_1(t)$ are monotone increasing and monotone decreasing, respectively, and there are $\lim_{t\to\infty} \chi_{\xi}(t) = \chi_{\xi}^0 \le \lim_{t\to\infty} \chi_1(t) = \chi_1^0$. From (3.14), the equation has only unique normal number solutions when $R_0 > 1$, i.e. $\chi_{\xi}^0 = \chi_1^0 = \xi^*$, the $\chi(t)$ corresponding to the i(a, t) also obtain $\lim_{t\to\infty} \chi(t) = \xi^*$. Reuse (3.13) when $t > A_0$, can be obtained $\lim_{t\to\infty} i(a, t) = i(a)$, i.e. the local disease equilibrium of (3.10) is globally attractive. The stability of the local disease equilibrium can be obtained by linearization. Therefore, the local disease equilibrium is globally asymptotically stable.

Remark 3.3. 3.2 shows that the epidemic disease will die out if $R_0 < 1$, while the disease will be prevalent if $R_0 > 1$. This implies that R_0 is the threshold of model (2.4).

4. Optimal control strategies

4.1. Formulation of the optimal control problem

In section 3, we consider the effect of a age determined vaccine immunization of the system on threshold dynamics, which is one of the cases in which vaccines are added to all susceptible persons in the system. In this section, we focus on the optimal control of (4.1) on the basis of age-structured SIRS by implementing proportion of vaccination u(a, t) as control strategy at all ages of system, and vaccination rate u(a, t) satisfies $0 \le u(a, t) \le 1$. We aim to minimize the infected population, while keeping the cost of applying such control strategy at the minimum level.

Let $((a, t_0), x(a, t_0)) \in [0, T) \times (\mathbb{H} \times \mathbb{H} \times \mathbb{H})$, and consider the following control system over on $(a, t) \in (0, A) \times [t_0, T]$:

$$\begin{pmatrix}
\frac{S(a,t)}{\partial t} + \frac{\partial S(a,t)}{\partial a} = \lambda(a) - \mu(a)S(a,t) - \beta(a)S(a,t)I(a,t) + \rho(a)\eta(a)I(a,t) \\
+\gamma(a)R(a,t) - u(a,t)S(a,t), \\
\frac{I(a,t)}{\partial t} + \frac{\partial I(a,t)}{\partial a} = \beta(a)S(a,t)I(a,t) - \delta(a)I(a,t)), \\
\frac{R(a,t)}{\partial t} + \frac{\partial R(a,t)}{\partial a} = (1 - \rho(a))\eta(a)I(a,t) - (\mu(a) + \gamma(a))R(a,t) + u(a,t)S(a,t), \\
S(a,t_0) = S_{t_0}(a), \quad I(a,t_0) = I_{t_0}(a), R(a,t_0) = R_{t_0}(a),
\end{cases}$$
(4.1)

where $S(a, t_0) = S_{t_0}(a)$, $I(a, t_0) = I_{t_0}(a)$, $R(a, t_0) = R_{t_0}(a)$ is varying initial time value and denote the initial state $x(a, t_0)$ as $x_{t_0}(a)$. Here the control $\{u(\cdot, \cdot) : (0, A) \times [t_0, T] \rightarrow \mathcal{U}\}$, and $u(\cdot, \cdot)$ is measurable. We obtain the schematic diagram of model (4.1) with introducing vaccination control (see Figure 1).



Figure 1. Schematic diagram of the model (4.1).

The object is to design the optimal controller $u^*(a, t)$, $(a, t) \in (0, A) \times [t_0, T]$ for the system (4.1) which minimizes the following performance index during the finite time interval $[t_0, T]$ [27–30]. Our goal is to minimize the total number of the infected and susceptible individuals by using minimal control efforts. The cost function as follows

$$J(t_0, x_{t_0}(a), u(a, t)) = \int_{t_0}^T \int_0^A (\tau_1 I(a, t) + \tau_2 u(a, t) + \frac{1}{2} \tau_3 u^2(a, t)) dadt + \int_0^A h(I(a, T)) da, \qquad (4.2)$$

where $I(a,t) : (a,t) \in [0,A] \times [t_0,T]$ and we denote $x = (S,I,R), x_{t_0} \in (\mathbb{H} \times \mathbb{H} \times \mathbb{H})$, the terminal value is $V(x,T) = \int_0^A h(I(a,T))da$. Let $L(t,x,u) := \tau_1 I(a,t) + \tau_2 u(a,t) + \frac{1}{2}\tau_3 u^2(a,t)$, where τ_1, τ_2

Mathematical Biosciences and Engineering

and τ_3 are the positive weighting factors, representing the cost per unit time of the components I(a, t), u(a, t) and $u^2(a, t)$, respectively. In particular, $\int_{t_0}^T \int_0^A \tau_1 I(a, t) da dt$ is the cost that infected individual creates for the society due to standard medical care, not including the vaccination treatment u(a, t). $\int_{t_0}^T \int_0^A (\tau_2 u(a, t) + \frac{1}{2}\tau_3 u^2(a, t)) da dt$ is the cost of treating infected individuals. $h : \mathbb{H} \times \mathbb{H} \to \mathbb{H}$ are measurable and h(I(a, T)) denotes the total number disease in population depend on the age at the time *T*. The value function as

$$\begin{cases} V(t_0, x_{t_0}(a)) = \inf_{u(\cdot) \in \mathcal{U}} J(t_0, x_{t_0}(a), u(a, t)), \quad \forall t_0 \in [0, T), \\ V(T, x_{t_0}(a)) = \int_0^A h(I(a, T)) da. \end{cases}$$
(4.3)

The function $V(\cdot, \cdot)$ will play an important role in obtaining optimal control, thus, we would like to study $V(\cdot, \cdot)$ in great detail. Let (x^*, u^*) is optimal pair, where $x^* = (S^*, I^*, R^*)$. Noting that the initial time (t = 0) and the initial state $(x(a, 0) = x_0)$ are fixed in the model [18]. The h(I(a, T)) satisfies

$$\int_{0}^{A} |h(I(a,T)) - h(\tilde{I}(a,T))| \, da \le C ||I(a,T) - \tilde{I}(a,T)||_{C},\tag{4.4}$$

where *C* is a positive constant, $\|\cdot\|$ represents norm on space \mathbb{H} and I(a, T), $\tilde{I}(a, T) \in \mathbb{H}$. The following hypothesis are put forward and need to be satisfied.

D1 (\mathcal{U} , d) is a separable metric space and T > 0.

D2 The control set \mathcal{U} is bounded convex

D3 Different controls correspond to same terminal value.

Then we study dynamic programming method, to give optimal strategy of model (4.1). The basic idea of this approach applied to optimal controls is to consider a family of optimal control problems with different initial times ($t = t_0 \ge 0$) and initial states ($x(a, t_0) = x_{t_0}(a)$) [see [31–33]], to establish relationships among these problems through the HJB equation. Firstly, we present the Bellman's principle of optimality as follows.

Theorem 4.1. Let (D1)-(D3) hold. Then for any $(t_0, x_{t_0}(a)) \in [0, T) \times \mathbb{H} \times \mathbb{H} \times \mathbb{H}$,

$$V(t_0, x_{t_0}(a)) = \inf_{u(\cdot) \in \mathcal{U}[t_0, T]} \left\{ \int_{t_0}^{t_0} \int_0^A L(t, x(t; t_0, x_{t_0}(a), u(\cdot, \cdot)), u(a, t)) dt + V(\hat{t}_0, x(\hat{t}_0; t_0, x_{t_0}(a), u(\cdot, \cdot))) \right\}, \quad \forall 0 \le t_0 \le \hat{t}_0 < T.$$

$$(4.5)$$

where $L(t, x(t; t_0, x_{t_0}(a), u(\cdot, \cdot)), u(a, t)) = \tau_1 I_{t_0}(a) + \tau_2 u(a, t) + \frac{1}{2} \tau_3 u^2(a, t).$

Proof. Let us denote the right-hand side of (4.5) by $\overline{V}(t_0, x_{t_0}(a))$. By (4.3), we have

$$V(t_0, x_{t_0}(a)) \leq J(t_0, x_{t_0}(a), u(a, t))$$

= $\int_{t_0}^{\hat{t}_0} \int_0^A (\tau_1 I(a, t) + \tau_2 u(a, t) + \frac{1}{2} \tau_3 u^2(a, t)) dadt$
+ $J(\hat{t}_0, x(a, \hat{t}_0), u(\cdot, \cdot)), \quad \forall u(\cdot, \cdot) \in \mathcal{U}.$

Thus, taking the infimum over $u(\cdot, \cdot) \in \mathcal{U}$ we get

$$V(t_0, x_{t_0}(a)) \le V(t_0, x_{t_0}(a)).$$
(4.6)

Mathematical Biosciences and Engineering

Conversely, for any $\varepsilon > 0$, there exists a $u_{\varepsilon}(\cdot, \cdot) \in \mathcal{U}$ such that

$$V(t_0, x_{t_0}(a)) + \varepsilon \ge J(t_0, x_{t_0}(a), u_{\varepsilon}(\cdot, \cdot))$$

$$\ge \int_{t_0}^{\hat{t}_0} \int_0^A (\tau_1 I_{\varepsilon}(a, t) + \tau_2 u_{\varepsilon}(a, t) + \frac{1}{2} \tau_3 u_{\varepsilon}^2(a, t)) dadt + V(\hat{t}_0, x_{\varepsilon}(a, \hat{t}_0))$$

$$\ge \overline{V}(t_0, x_{t_0}(a)).$$
(4.7)

Combing (4.6) and (4.7), we obtain (4.5).

The equation (4.5) is dynamic programming equation, which gives a relationship among globally and locally optimal via value function.

We would like to further study the (4.5), trying to obtain an equation for $V(t_0, x_{t_0}(a))$ simpler form. The following results give a partial differential equation that a continuously differentiable value function ought to satisfy. We know the $V(t_0, x_{t_0}(a))$ is a continuously differentiable value function via 4.1 and basic theorem of calculus.

Define the Lyapunov equation (LE)

$$\langle V_x, (f(a,t,x) + g(a,t,x)u(a,t)) \rangle + \int_0^A (\tau_1 I(a,t) + \tau_2 u(a,t) + \frac{1}{2} \tau_3 u^2(a,t)) da = 0.$$

That is

$$0 = \langle V_S, \left(-\frac{\partial S}{\partial a} + \lambda(a) - \mu(a)S - \beta(a)SI + \rho(a)\eta(a)I + \gamma(a)R - u(a,t)S\right) \rangle + \langle V_R, \left(-\frac{\partial R}{\partial a} + (1 - \rho(a))\eta(a)I - (\mu(a) + \gamma(a))R + u(a,t)S\right) \rangle + \langle V_I, \left(-\frac{\partial I}{\partial a} + \beta(a)SI - \delta(a)I\right) \rangle + \int_0^A (\tau_1 I(a,t) + \tau_2 u(a,t) + \frac{1}{2}\tau_3 u^2(a,t))da = \int_0^A V_S(-\frac{\partial S}{\partial a} + \lambda(a) - \mu(a)S - \beta(a)SI + \rho(a)\eta(a)I + \gamma(a)R - u(a,t)S)da + \int_0^A V_R(-\frac{\partial R}{\partial a} + (1 - \rho(a))\eta(a)I - (\mu(a) + \gamma(a))R + u(a,t)S)da + \int_0^A V_I(-\frac{\partial I}{\partial a} + \beta(a)SI - \delta(a)I)da + \int_0^A (\tau_1 I(a,t) + \tau_2 u(a,t) + \frac{1}{2}\tau_3 u^2(a,t))da,$$

$$(4.8)$$

where $V_x = (\frac{\partial V}{\partial S}, \frac{\partial V}{\partial I}, \frac{\partial V}{\partial R})^{\top}$, $V_t = \frac{\partial V}{\partial t}$. The equation LE is the HJB equation when u(a, t) is optimal control of (4.1).

$$\begin{aligned} V_{0} &= \int_{0}^{A} V_{S}(-\frac{\partial S}{\partial a} + \lambda(a) - \mu(a)S - \beta(a)SI + \rho(a)\eta(a)I + \gamma(a)R - u(a,t)S)da \\ &+ \int_{0}^{A} V_{R}(-\frac{\partial R}{\partial a} + (1 - \rho(a))\eta(a)I - (\mu(a) + \gamma(a))R + u(a,t)S)da \\ &+ \int_{0}^{A} V_{I}(-\frac{\partial I}{\partial a} + \beta(a)SI - \delta(a)I)da + \int_{0}^{A} (\tau_{1}I(a,t) + \tau_{2}u(a,t) + \frac{1}{2}\tau_{3}u^{2}(a,t))da, \end{aligned}$$
(4.9)
$$V_{|t=T} = h(x), \qquad x \in \mathbb{H} \times \mathbb{H} \times \mathbb{H}.$$

Mathematical Biosciences and Engineering

Volume 18, Issue 6, 9474-9495.

In this subpart, we write the HJB equation of model (4.1) as well as its viscosity solution is discussed as following.

Theorem 4.2. Let (**D1**)-(**D3**) and $V(t, x) \in C^1([0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H})$. Then V(t, x) is a solution of the following terminal value problem of HJB equation:

$$\begin{cases} V_t + \inf_{u \in \mathcal{U}} H(t, x, u, V_x) = 0, & t \in [0, T), \\ V|_{t=T} = h(x), & \forall (t, x, u) \in [0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H} \times \mathcal{U}. \end{cases}$$
(4.10)

which can be written as (4.9).

Proof. Fix $(t_0, x_{t_0}(a)) \in [0, T) \times \mathbb{H} \times \mathbb{H} \times \mathbb{H}$ and $u \in \mathcal{U}$. Let $x(\cdot, \cdot)$ be the state trajectory corresponding to the control $u(\cdot, \cdot) \in \mathcal{U}^{\omega}[s, T]$ with $u(a, t) \equiv u$. On the one hand, we can write according to (4.5)

$$0 \ge \{V(\hat{t}_0, x(\hat{t}_0, a)) - V(t_0, x_{t_0}(a))\} - \int_{t_0}^{\hat{t}_0} \int_0^A (\tau_1 I(a, t) + \tau_2 u(a, t) + \frac{1}{2} \tau_3 u^2(a, t)) da dt.$$
(4.11)

Rearranging the equation (4.11) and dividing the both side of the equation by $\hat{t}_0 - t_0$ yield

$$0 \geq -\frac{\{V(\hat{t}_{0}, x(a, \hat{t}_{0})) - V(t_{0}, x_{t_{0}}(a))\}}{\hat{t}_{0} - t_{0}} - \frac{1}{\hat{t}_{0} - t_{0}} \int_{t_{0}}^{\hat{t}_{0}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))dadt = -\frac{\{V(\hat{t}_{0}, x(a, \hat{t}_{0})) - V(\hat{t}_{0}, x_{t_{0}}(a)) + V(\hat{t}_{0}, x(a, \hat{t}_{0})) - V(t_{0}, x(a, \hat{t}_{0}))\}}{\hat{t}_{0} - t_{0}} - \frac{1}{\hat{t}_{0} - t_{0}} \int_{t_{0}}^{\hat{t}_{0}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))dadt.$$

$$(4.12)$$

By (4.5) with $\hat{t}_0 \downarrow t_0$, we obtain

$$0 \geq -V_{t}(t_{0}, x_{t_{0}}(a)) - \langle V_{x}(t_{0}, x_{t_{0}}(a)), \frac{dx}{dt} \rangle - \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))da$$

$$= -\int_{0}^{A} \left\{ V_{S}(t_{0}, x_{t_{0}}(a)) \left(-\frac{\partial S(a, t)}{\partial a} + \lambda(a) - \mu(a)S(a, t) - \beta(a)S(a, t)I(a, t) + \rho(a)\eta(a)I(a, t) + \gamma(a)R(a, t) - u(a, t)S(a, t) \right) - V_{I}(t_{0}, x_{t_{0}}(a)) \left(-\frac{\partial I(a, t)}{\partial a} + \beta(a)S(a, t)I(a, t) - \delta(a)I(a, t) \right) - V_{R}(t_{0}, x_{t_{0}}(a)) \left(-\frac{\partial R(a, t)}{\partial a} + (1 - \rho(a))\eta(a)I(a, t) - (\mu(a) + \gamma(a))R(a, t) + u(a, t)S(a, t) \right) \right\} da - \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))da.$$
(4.13)

Mathematical Biosciences and Engineering

This results in

$$0 \leq V_{t}(t, x(a, t))$$

$$+ \inf_{u \in \mathcal{U}} \int_{0}^{A} \left\{ V_{S}(t, x(a, t)) \left(-\frac{\partial S(a, t)}{\partial a} - \mu(a)S(a, t) - \beta(a)S(a, t)I(a, t) + \rho(a)\eta(a)I(a, t) \right. \\ \left. + \lambda(a) + \gamma(a)R(a, t) \right) + V_{I}(t, x(a, t)) \left(-\frac{\partial I(a, t)}{\partial a} + \beta(a)S(a, t)I(a, t) - \delta I(a, t) \right) \\ \left. + V_{R}(t, x(a, t)) \left(-\frac{\partial R(a, t)}{\partial a} + (1 - \rho(a))\eta(a)I(a, t) - (\mu(a) + \gamma(a))R(a, t) \right) \right\} da$$

$$+ \int_{0}^{A} \left(\tau_{1}I(a, t) - \tau S\left(V_{S}(t, x(a, t)) - V_{R}(t, x(a, t))\right) \\ \left. + \frac{1}{2\tau_{3}} \left(S\left(V_{S}(t, x(a, t)) - V_{R}(t, x(a, t))\right) \right)^{2} \right) da.$$

$$(4.14)$$

On the other hand, for any $\varepsilon > 0$, $\forall 0 \le t_0 \le \hat{t_0} < T$ with $\hat{t_0} - t_0 > 0$ small enough, there exists a $u(\cdot, \cdot) \equiv u_{\varepsilon, \hat{t_0}}(\cdot, \cdot) \in \mathcal{U}$ such that

$$V(t_0, x_{t_0}(a)) + \varepsilon(\hat{t}_0 - t_0) \ge V(\hat{t}_0, x(\hat{t}_0; t_0, x_{t_0}(a), u(a, t))) + \int_{t_0}^{\hat{t}_0} \int_0^A (\tau_1 I(a, t) + \tau_2 u(a, t) + \frac{1}{2} \tau_3 u^2(a, t)) da dt.$$
(4.15)

Thus, it follows that as (noting $V \in C^1([0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H}))$

$$-\varepsilon \leq -\frac{\{V(\hat{t}_{0}, x(\hat{t}_{0})) - V(t_{0}, x(t_{0}))\}}{\hat{t}_{0} - t_{0}} - \frac{1}{\hat{t}_{0} - t_{0}} \int_{t_{0}}^{\hat{t}_{0}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))dadt$$

$$\leq \frac{1}{\hat{t}_{0} - t_{0}} \int_{t_{0}}^{\hat{t}_{0}} [-V_{t}(t_{0}, x_{t_{0}}(a)) - \langle V_{x}(t_{0}, x_{t_{0}}(a)), \frac{dx}{dt} \rangle - \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))da]dt$$

$$\leq \frac{1}{\hat{t}_{0} - t_{0}} \int_{t_{0}}^{\hat{t}_{0}} [-V_{t}(t_{0}, x_{t_{0}}(a)) - \langle V_{x}(t_{0}, x_{t_{0}}(a)), \frac{dx}{dt} \rangle - \inf_{u \in \mathcal{U}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))da]dt$$

$$\leq \frac{1}{\hat{t}_{0} - t_{0}} \int_{t_{0}}^{\hat{t}_{0}} -V_{t}(t_{0}, x_{t_{0}}(a)) + \inf_{u \in \mathcal{U}} H(t, x(a, t), u(a, t), V_{x}(t, x(a, t)))dt.$$

$$(4.16)$$

Taking limit on (4.16) with respect to $\hat{t}_0 \downarrow t_0$, we have

$$0 \geq V_{t}(t, x(a, t)) + \inf_{u \in \mathcal{U}} \int_{0}^{A} \left\{ V_{S}(t, x(a, t)) \left(-\frac{\partial S(a, t)}{\partial a} - \mu(a)S(a, t) - \beta(a)S(a, t)I(a, t) + \rho(a)\eta(a)I(a, t) + \lambda(a) + \gamma(a)R(a, t) \right) + V_{I}(t, x(a, t)) \left(-\frac{\partial I(a, t)}{\partial a} + \beta(a)S(a, t)I(a, t) - \delta I(a, t) \right) + V_{R}(t, x(a, t)) \left(-\frac{\partial R(a, t)}{\partial a} + (1 - \rho(a))\eta(a)I(a, t) - (\mu(a) + \gamma(a))R(a, t) \right) \right\} da + \int_{0}^{A} \left(\tau_{1}I(a, t) - \tau S\left(V_{S}(t, x(a, t)) - V_{R}(t, x(a, t))\right) + \frac{1}{2\tau_{3}} \left(S\left(V_{S}(t, x(a, t)) - V_{R}(t, x(a, t))\right) \right)^{2} \right) da.$$

$$(4.17)$$

Mathematical Biosciences and Engineering

Combining (4.14) and (4.20), we obtain our results.

Definition 4.3. [34] A function $v \in C([0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H})$ is called a viscosity solution of (4.9) if

$$v(T, x(a, T)) \le h(x(a, T)), \quad \forall x(a, T) \in \mathbb{H} \times \mathbb{H} \times \mathbb{H},$$
(4.18)

and for any $\psi \in C^1([0,T] \times \mathbb{R})$, whenever $v - \psi$ attains a local maximum at $(t, x) \in [0,T) \times \mathbb{H} \times \mathbb{H} \times \mathbb{H}$, we have

$$\psi_t(t,x) + \sup_{u \in \mathcal{U}} H(t,x,u,-\psi_x(t,x)) \le 0.$$
(4.19)

The function $v \in C([0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H})$ is called a viscosity solution of (4.9) if in (4.18)-(4.19) the inequalities \leq are changed to \geq and local maximum is changed to local minimum. In the case that v is both a viscosity subsolution and supersolution of (4.9), it is called a viscosity solution of (4.9).

Theorem 4.4. Let (D1)-(D3) hold. Then the value function of V(t, x) satisfies

$$|V(t_0, x_{t_0}(a)) - V(\hat{t}_0, x_{\hat{t}_0}(a))| \le K\{|t_0 - \hat{t}_0|\}, \forall (t_0, x_{t_0}(a)), \ (\hat{t}_0, x_{\hat{t}_0}(a)) \in [0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H},$$
(4.20)

for some K > 0. Moreover, V(t, x(a, t)) is the only solution of (4.9) in the class $C([0, T] \times \mathbb{H} \times \mathbb{H} \times \mathbb{H})$. *Proof.* Through 4.2 and $t_0 \le \hat{t}_0$ we obtain

$$|V(t_{0}, x_{t_{0}}(a)) - V(\hat{t}_{0}, x_{\hat{t}_{0}}(a))|$$

$$\leq \inf_{u \in \mathcal{U}} \{ \int_{t_{0}}^{\hat{t}_{0}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))dadt \}$$

$$\leq \int_{t_{0}}^{\hat{t}_{0}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))dadt$$

$$\leq |t_{0} - \hat{t}_{0}| \max_{t_{0} \leq t \leq \hat{t}_{0}} \int_{0}^{A} (\tau_{1}I(a, t) + \tau_{2}u(a, t) + \frac{1}{2}\tau_{3}u^{2}(a, t))da$$

$$\leq K|t_{0} - \hat{t}_{0}|.$$
(4.21)

Thus, V(t, x(a, t)) satisfies (4.21). We can know that V(t, x(a, t)) is unique viscosity of the HJB equation via the same method as [[34], Theorem 2.5].

4.2. Optimal control

In this subsection, we study the existence of the optimal control pair in finite time for the system (4.1) and construct the Hamiltonian of the optimal control problem.

Theorem 4.5. There exists an optimal control $u^* \in \mathcal{U}$ and a corresponding optimal state S^* , I^* , R^* such that

$$V(t_0, x_{t_0}(a)) = \inf_{u(\cdot) \in \mathcal{U}} J(t_0, x_{t_0}(a), u^*(a, t)), \quad \forall (t_0, x_{t_0}(a)) \in [0, T) \times \mathbb{H} \times \mathbb{H} \times \mathbb{H},$$

subject to the control system (4.1).

Mathematical Biosciences and Engineering

Proof. To show the existence of the optimal control for the problem under consideration, we use the result in [35,36]. We notice that the state and control variables are non-negative, and the control set \mathcal{U} , by definition, is closed and bounded. The optimal system is bounded, which ensures the compactness needed for the existence of an optimal control. Further, the integrand $\int_{t_0}^T \int_0^A (\tau_1 I(a, t) + \tau_2 u(a, t) + \frac{1}{2}\tau_3 u^2(a, t)) dadt$ is convex on the control set \mathcal{U} due to the biquadratic and quadratic nature of control variable u(a, t), which represents vaccination proportion. In addition, there exists a constant $\nu > 1$ and positive numbers κ_1 , κ_2 such that

$$\tau_1 I(a,t) + \tau_2 u(a,t) + \frac{1}{2} \tau_3 u^2(a,t) \ge \kappa_1 |u(a,t)|^{\nu} - \kappa_2.$$

We complete the existence of the optimal control of state variables.

Theorem 4.6. Let $u^*(a, t)$ be optimal control variable, $S^*(a, t)$, $I^*(a, t)$ and $R^*(a, t)$ be corresponding optimal state variable of model (4.1). The corresponding optimal control is given as follows:

$$u^{*}(a,t) = \min\{\max[0, -\frac{1}{\tau_{3}}S(a,t)^{*}(V_{R}(x,t) - V_{S}(x,t)) + \tau], 1\}$$

where $\frac{\tau_2}{\tau_3} = \tau$.

Proof. We define the Hamiltonian function $H(t, x, u(a, t), V_x)$, $t \in [0, T]$, $u(a, t) \in \mathcal{U}_{ad}$, $x, V_x(x, t) \in \mathbb{H} \times \mathbb{H} \times \mathbb{H}$ and by constructing the Hamiltonian function and HJB equation to characterize this optimal control u(a, t) as follows:

$$H = \left(-\frac{\partial S}{\partial a} + \lambda(a) - \mu(a)S - \beta(a)SI + \rho(a)\eta(a)I + \gamma(a)R - u(a,t)S\right)V_S(x,t) + \left(-\frac{\partial I}{\partial a} + \beta(a)SI - \delta(a)I\right)V_I(x,t) - \tau_1I - \tau_2u(a,t) - \frac{1}{2}\tau_3u^2(a,t) + \left(-\frac{\partial R}{\partial a} + (1 - \rho(a))\eta(a)I - (\mu(a) + \gamma(a))R + u(a,t)S\right)V_R(x,t).$$

$$(4.22)$$

Let $u^*(a, t)$ be given optimal control and $S^*(a, t)$, $I^*(a, t)$ and $R^*(a, t)$ be corresponding optimal state variable of model (4.1). By the Hamiltonian function (4.22), optimal control $u(a, t) = u^*(a, t)$ is obtained

$$u^{*}(a,t) = -\frac{1}{\tau_{3}}S(a,t)^{*}(V_{R}(x,t) - V_{S}(x,t)) + \tau_{.}$$
(4.23)

From the properties of the control set with the findings, then there is exists optimal control

$$u^{*}(a,t) = \begin{cases} 0, & -\frac{1}{\tau_{3}}S^{*}(V_{R}-V_{S}) + \tau < 0, \\ -\frac{1}{\tau_{3}}S^{*}(V_{R}(x,t) - V_{S}(x,t)) + \tau, & 0 \le -\frac{1}{\tau_{3}}S^{*}(V_{R}-V_{S}) + \tau < 1, \\ 1, & 1 \le -\frac{1}{\tau_{3}}S^{*}(V_{R}-V_{S}) + \tau. \end{cases}$$
(4.24)

Mathematical Biosciences and Engineering

Remark 4.7. If we could obtain the value function V(t, x(a, t)) by solving the HJB equation, then we could, at least formally, construct an optimal pair for each of optimal control problem for different initial values. The principle involves the following steps to solve optimal control problem

Step.1. Solve the HJB equation (4.10) to find the V(T, x(a, t)); Step.2. Find $u^*(a, t)$ through Hamiltonian function (4.22); Step.3. Combine the $u^*(a, t)$ to solve model (4.1) to get the optimal pair ($x^*(a, t), u^*(a, t)$).

5. Numerical simulation

This section aims to illustrate the effectiveness of our theoretical results obtained in previous sections.

5.1. Numerical simulation of the stability of equilibria

Parameter	Value	Source of data
λ	0.20548	[16], Lan et al.
eta	1.6805×10^{-4}	[16], Lan et al.
μ	3.4246×10^{-5}	[18], Mu & Zhang
η	0.02	[18], Mu & Zhang
ho	0.05	[18], Mu & Zhang
γ	0.027	[16], Lan et al.
δ	0.2227	Assumed
ϱ	0.2	Assumed
и	0.35	Assumed
A	80 years	[16], Lan et al.
Т	500 days	Assumed

Table 2. Parameter values used in numerical simulations.

In the numerical simulation, the parameters are given in Table 2. We assume that $(a, t) \in [0, 80] \times [0, 500]$, $\Delta t = 0.1$, $\Delta a = 1$, take $p_{\infty} = 1.0$, $\rho = 0.2$, $\delta = 0.1827$, k = 0.2, then $R_0 \approx 2.69 > 1$. The parameters that we partially need to assume are reasonable according to the study of Yang et al. [14] has shown that the range of the basic reproduction number of the pandemic influenza in 1.0 - 4.0. We see from 3.2 the E^* is globally asymptotically stable. Actually, as showing in the following Figure 2 (a), the density of the infected individual I(a, t) tends to be a positive constant over time.

Take $\rho = 0.1$, $\delta = 0.1827$, k = 0.1, then $R_0 \approx 0.78 < 1$, thus we can know the E^0 is globally asymptotically stable, as showing in the following Figure 2 (b), the density of the infected individual I(a, t) tends to zero over time. These are the same conclusions as 3.2.

We choose $\delta = 0.1827$, 0.2027 and 0.2227 to study the effect on the infected population and all the other parameters are fixed as in Table 2. We calculate the corresponding basic reproduction number $R_0 \approx 0.9427$, 0.8979 and 0.7802 when $R_0 < 1$, respectively. In Figure 3 (a), we can see that the extinction time of decreases with the increase of infected removal rate δ . In order to simulate the cases of $R_0 > 1$, we calculate the corresponding basic reproduction number $R_0 \approx 1.3468$, 2.2441 and 2.6930,



Figure 2. The evolution of I(a, t) of (2.4) for $R_0 \approx 2.69 > 1$ (a) and $R_0 \approx 0.78 < 1$ (b).

respectively. The simulation result is presented in Figure 3 (b). Synthetically, it is obvious to see from Figure 3 that the peak of I(a, t) decreases significantly as infected removal rate δ of age a goes up.



Figure 3. (a): the path of I(a, t) under different δ when $R_0 < 1$ at age a = 30; (b): the path of I(a, t) under different δ when $R_0 > 1$ at age a = 30.

5.2. Numerical simulation for optimal control

In this section, we show the result of optimal control using a numerical example. The parameters are given in Table 2. $(a, t) \in [0, 80] \times [0, 500]$, $\Delta t = 0.1$, $\Delta a = 1$ by performing some numerical simulations. We take $\tau_1 = 11.7$, $\tau_2 = 3.4$ and $\tau_3 = 12$. The corresponding paths of control and infective populations I(a, t) are plotted in Figure 4, Figure 5 (a), Figure 6 and Figure 7 (a) show the section view at age a = 20 and a = 30 of the image variation tendency of I(a, t) with and without control and the tendency of corresponding optimal control u(a, t). We observe that the comprehensive use of control u(a, t) works better than no control applied during the course of disease. The effect of applying control reduces the number of infective populations I(a, t) dramatically. In short, control variable u(a, t) play an important role in the control of the disease. At the same time, we can also observe a reduced epidemic time of population infection.

We note that a significant decline in the number of infected persons I(a, t) during vaccine control of

susceptible at age a = 20 and a = 30 from these following figures.



Figure 4. When $R_0 > 1$, (a): the paths of I(a, t) with and without control u(a, t) at age a = 20; (b): The paths of I(a, t) with and without control u(a, t) at age a = 30.



Figure 5. (a): when $R_0 > 1$, the paths of control at age a = 20 and a = 30; (b): the path of control at t = 500.

When $R_0 > 1$, I(a, t) trends is regard to the optimal controls, where the upper-level image is the evolution of I(a, t) without control and the lower-level image is the evolution of I(a, t) with control on in Figure 4. In Figure 5 (a) shows the optimal control pathes at ages a = 20 and a = 30, repectively. Eventually the disease tends to extinction with control. Compared with the path of non-vaccinated I(a, t), the epidemic time of I(a, t) with vaccination is significantly shortened, as well as the density of infected population verge to zero eventually.



Figure 6. When $R_0 < 1$, (a): the paths of I(a, t) with and without control u(a, t) at age a = 20; (b): The paths of I(a, t) with and without control u(a, t) at age a = 30.



Figure 7. (a): when $R_0 < 1$, the paths of control at age a = 20 and a = 30; (b): the paths of control at t = 500.

When $R_0 < 1$, I(a, t) trends is regard to the optimal controls, where the upper-level image is the evolution of I(a, t) without control and the lower-level image is the evolution of I(a, t) with control in Figure 6. In Figure 7 (a) shows the optimal control pathes at ages a = 20 and a = 30, repectively. Eventually the disease tends to extinction with control. Compared with Compared with the path of non-vaccinated I(a, t), the epidemic time of I(a, t) with vaccination is significantly shortened. Combined with Figure 4 and the corresponding conclusions, it is clear that vaccination have a certain degree of hindrance to the transmission of epidemics. We also observe the Figure 5 (b) and Figure 7 (b) that vaccine control varies for different ages, mainly adolescents and middle age, and this control strategy is consistent with the actual control of many epidemics such as pneumonia, influenza and so on. The pneumococcal vaccine, COVID-19 vaccine and influenza vaccine are not suitable for the elderly. Overall, population age has a significant effect on the implementation of vaccine control strategies for many common diseases.

6. Concluding remarks

In this paper, we recurred an age-structured SIRS epidemic model (2.1) with vaccination control, and obtained the condition for disease extinction and persistence. The research results showed that when $R_0 < 0$, the disease extincted; when $R_0 > 0$, the disease persisted. The conditions of disease extinction and permanence were given in 3.2. And we verified the resluts by numerical simulation. However, since the bifurcation phenomenon will occur when $R_0 = 0$, this part will also be an important point for our further study of the age-structured SIRS epidemic system dynamics. Besides, we also studied the control problem of SIRS epidemic model with age structure. By proving the existence of viscosity solution, we obtain the existence of optimal control. Then, we obtained the implicit expression for optimal control and HJB equation. Finally, by using Milstein method, the optimal proportion of vaccination is obtained. In addition, we plan that in the next step, traveling wave solutions of an age-structured SIRS epidemic model will become one of our main research contents. Wu et al. [37] studied the existence of traveling wave solutions for a diffusive age-structured SIR epidemic model. Their work provides some insights on how to deal with the high dimensional age-structured epidemic models.

Acknowledgments

The authors thank the editor and referees for their careful reading and valuable comments. The research was supported in part by the Ningxia Natural Science Foundation (No. 2020AAC03067).

Conflict of interest

The authors have no conflict of interest.

References

- 1. W. O. Kermack, A. G. McKendrick, A contribution to the mathematical theory of epidemics, *Proc. R. Soc. London, Ser. A*, **115** (1927), 700–721.
- 2. N. P. Ahmad, Global dynamics of a fractional-order SIR epidemic model with memory, *Int. J. Biomath.*, **13** (2020), 500710.
- 3. P. A. Naik, J. Zu, K. M. Owolabi, Global dynamics of a fractional order model for the transmission of HIV epidemic with optimal control, *Chaos Solitons Fractals*, **138** (2020), 109826.
- 4. P. A. Naik, J. Zu , K. M. Owolabi, Modeling the mechanics of viral kinetics under immune control during primary infection of HIV-1 with treatment in fractional order, *Physica A*, **545** (2020), 123816.
- 5. J. Zu, M. Li, Y. Gu, S. Fu, Modelling the evolutionary dynamics of host resistance-related traits in a susceptible-infected community with density-dependent mortality, *Discrete. Contin. Dyn. Syst. Ser. B*, **25** (2020), 3049–3086.
- 6. Y. Enatsu, Y. Nakata, Y. Muroya, Global stability of SIRS epidemic models with a class of nonlinear incidence rates and distributed delays, *Acta. Math. Sci.*, **32** (2012), 851–865.

- 8. K. Cooke, S. Busenberg, Vertically transmitted disease, in *Nonlinear Phenomena in Mathematical Sciences* (Edited by V. Lakshmikantham), Academic Press, New York, 1982.
- 9. J. Zu, M. Li, G. Zhuang, P. Liang, F. Cui, F. Wang, et al., Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model, *Medicine*, **97** (2018), e0484.
- 10. J. Yang, Z. Jin, L. Wang, F. Xu, A note on an age-of-infection SVIR model with nonlinear incidence, *Int. J. Biomath.*, **10** (2017), 500644.
- 11. T. Kuniya, Global stability analysis with a discretization approach for an age-structured multigroup SIR epidemic model, *Nonlinear Anal. Real World Appl.*, **12** (2011), 2640–2655.
- 12. Z. He, J. Cheng, C. Zhang, Optimal birth control of age-dependent competitive species, *J. Math. Anal. Appl.*, **296** (2008), 286–301.
- 13. J. Yang, Z. Jin, F. Xu, Threshold dynamics of an age-space structured SIR model on heterogeneous environment, *Appl. Math. Lett.*, **96** (2019), 69–74.
- F. Yang, L. Yuan, X. Tan, C. Huang, J. Feng, Bayesian estimation of the effective reproduction number for pandemic influenza a H1N1 in Guangdong province, *Ann. Epidemiol.*, 23 (2013), 301–306.
- 15. P. A. Naik, J. Zu, M. Ghoreishi, Stability analysis and approximate solution of SIR epidemic model with Crowley-Martin type functional response and holling type-II treatment rate by using homotopy analysis method, *J. Appl. Anal. Comput.*, **10** (2020), 1482–1515.
- 16. G. Lan, S. Yuan, B. Song, The impact of hospital resources and environmental perturbations to the dynamics of SIRS model, *J. Franklin Ins.*, **358** (2021), 2405–2433.
- 17. C. Abdennasser, F. M. Nor, K. Toshikazu, T. T. Mohammed, Global stability of an age-structured epidemic model with general Lyapunov functional, *Math. Biosci. Eng.*, **16** (2019), 1525–1553.
- 18. X. Mu, Q. Zhang, Near-optimal control for a stochastic multi-strain epidemic model with age structure and Markovian switching, *Int. J. Control*, 2020.
- 19. L. Bolzoni, E. Bonacini, R. D. Marca, M. Groppi, Optimal control of epidemic size and duration with limited resources, *Math. Biosci.*, **315** (2019), 108232.
- 20. Y. Zhou, J. Wu, M. Wu, Optimal isolation strategies of emerging infectious diseases with limited resources, *Math. Biosci. Eng.*, **10** (2013), 1691–1701.
- 21. H. Behncke, Optimal control of deterministic epidemics, *Optim. Control Appl. Methods*, **21** (2000), 269–285.
- 22. B. Luca, B. Elena, S. Cinzia, G. Maria, Time-optimal control strategies in SIR epidemic models, *Math. Biosci.*, **292** (2017), 86–96.
- 23. E. Hansen, T. Day, Optimal control of epidemics with limited resources, *J. Math. Biol.*, **62** (2011), 423–451.
- 24. M. T. Meehan, D. G. Cocks, J. M. Trauer, E. S. McBryde, Coupled, multi-strain epidemic models of mutating pathogens, *Math. Biol.*, **296** (2018), 82–92.

- 25. S. Lenhart, J. T. Workman, Optimal control applied to biological models, Crc. Press, 2007.
- 26. S. N. Busenberg, M. Iannelli, H. R. Thieme, Global behavior of an age-structured epidemic model, *SIAM J. Math. Anal.*, **22** (2006), 522069.
- 27. T. Cheng, F. L. Lewis, M. Abu-Khalaf, A neural network solution for fixed-final time optimal control of nonlinear systems, *Automatica*, **43** (2006), 482–490.
- 28. S. M. Mirhosseini-Alizamini, S. Effati, A. Heydari, An iterative method for suboptimal control of linear time-delayed system, *Syst. Control Lett.*, **82** (2015), 40–50.
- 29. Z. Zhao, Y. Yang, H. Li, D. Liu, Approximate finite-horizon optimal control with policy iteration, *IEEE Proc. 33rd Chinese Control Conference (CCC)*, 2014, 8889–8894.
- Q. Zhao, H. Xu, S. Jagannathan, Neural network-based finite-horizon optimal control of uncertain affine nonlinear discrete-time systems, *IEEE Trans. Neural Netw. Learn. Syst.*, 26 (2015), 486– 499.
- 31. H. Xu, Q. Zhao, J. Sarangapani, Neural network-based finite-horizon approximately optimal control of uncertain affine nonlinear continuous-time systems, *IEEE 2014 American Control Conference (ACC)*, 2014, 1243–1248.
- 32. H. Xu, S. Jagannathan, Neural network-based finite horizon stochastic optimal control design for nonlinear network control systems, *IEEE Trans. Neural Netw. Learn. Syst.*, **26** (2015), 472–485.
- 33. Q. Zhao, H. Xu, T. Dierks, S. Jagannathan, Finite-horizon network-based optimal control design for affine nonlinear continuous-time systems, *IEEE International Joint Conference on Neural Networks (IJCNN)*, 2013, 4–9.
- 34. J. Yong, X. Y. Zhou, Stochastic controls: Hamiltonian systems and HJB equations, Springer Science Business Media, 1999.
- 35. E. A. Murray, M. M. Seyed, R. Gergely, J. Wu, A delay differential model for pandemic influenza with antiviral treatment, *Bull. Math. Biol.*, **70** (2007), 382–397.
- 36. D. Lukes, Differential Equations: Classical to controlled, In Math. Sci. Eng., 1982.
- 37. S. Wu, L. Chen, C. Hsu, Traveling wave solutions for a diffusive age-structured SIR epidemic model, *Commun. Nonlinear Sci. Numer. Simul.*, **98** (2021), 105769.



 \bigcirc 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)